A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Sponsor

Washington University School of Medicine (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05903131

Collaborator

(none)

Enrollment

Locations

Arms

Anticipated Duration (Months)

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with endometrial hyperplasia or grade 1 endometrial cancer who desire uterine preservation will be more likely to have atypia-free uterine preservation at two years if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.

Condition or Disease	Intervention/Treatment	Phase
Endometrial Hyperplasia Grade 1 Endometrial Cancer	Behavioral: Telemedicine behavioral weight intervention Drug: Progestin Behavioral: Enhanced usual care Drug: Levonorgestrel-releasing IUD.	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

96 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Anticipated Study Start Date :

Oct 31, 2023

Anticipated Primary Completion Date :

Oct 31, 2028

Anticipated Study Completion Date :

Oct 31, 2030

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm 1: Levonorgestrel-releasing IUD (LNG-IUD) + Behavioral Weight Loss Intervention The levonorgestrel-releasing IUD is used in this study as per standard care. The behavioral weight loss intervention consists of a telemedicine cognitive behavioral coaching program. At each session, patients will self-report weight, number of days they kept a food journal during the past week, average daily caloric intake for the week, number of days exercised for the week, total number of minutes of moderate physical activity, and average number of steps per day for the week.	Behavioral: Telemedicine behavioral weight intervention Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (13 months total). Each telephone session will be 30 minutes long. Drug: Progestin Released via the levonorgestrel-releasing IUD. Drug: Levonorgestrel-releasing IUD. Standard of care
Active Comparator: Arm 2: Levonorgestrel-releasing IUD (LNG-IUD) + Enhanced Usual Care The levonorgestrel-releasing IUD is used in this study as per standard care. Participants will be provided with 1- to 3-page handouts on topics including healthy eating, exercise, and behavioral eating strategies from materials provided on the American Cancer Society, Society of Gynecologic Oncology, and WebMD Nourish websites. These materials encourage weight loss through calorie counting, recording dietary intake, engaging in exercise programs, and using portion control strategies. If participants in the enhanced usual care group do not achieve atypia-free uterine preservation (i.e., have not resolved their hyperplasia or grade 1 endometrial cancer) by one year of enrollment and continue to desire uterine preservation with progestin treatment, they will cross over to receive the telemedicine behavioral intervention for the second year.	Behavioral: Enhanced usual care 1-3 page handouts Drug: Levonorgestrel-releasing IUD. Standard of care

Arm

Intervention/Treatment

Experimental: Arm 1: Levonorgestrel-releasing IUD (LNG-IUD) + Behavioral Weight Loss Intervention

The levonorgestrel-releasing IUD is used in this study as per standard care. The behavioral weight loss intervention consists of a telemedicine cognitive behavioral coaching program. At each session, patients will self-report weight, number of days they kept a food journal during the past week, average daily caloric intake for the week, number of days exercised for the week, total number of minutes of moderate physical activity, and average number of steps per day for the week.

Behavioral: Telemedicine behavioral weight intervention

Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (13 months total). Each telephone session will be 30 minutes long.

Drug: Progestin

Released via the levonorgestrel-releasing IUD.

Drug: Levonorgestrel-releasing IUD.

Standard of care

Active Comparator: Arm 2: Levonorgestrel-releasing IUD (LNG-IUD) + Enhanced Usual Care

The levonorgestrel-releasing IUD is used in this study as per standard care. Participants will be provided with 1- to 3-page handouts on topics including healthy eating, exercise, and behavioral eating strategies from materials provided on the American Cancer Society, Society of Gynecologic Oncology, and WebMD Nourish websites. These materials encourage weight loss through calorie counting, recording dietary intake, engaging in exercise programs, and using portion control strategies. If participants in the enhanced usual care group do not achieve atypia-free uterine preservation (i.e., have not resolved their hyperplasia or grade 1 endometrial cancer) by one year of enrollment and continue to desire uterine preservation with progestin treatment, they will cross over to receive the telemedicine behavioral intervention for the second year.

Behavioral: Enhanced usual care

1-3 page handouts

Drug: Levonorgestrel-releasing IUD.

Standard of care

Outcome Measures

Primary Outcome Measures

Number of participants with atypia-free biopsy with uterine preservation [At 2 years (or exit from study)]

Secondary Outcome Measures

Atypia-free survival [Through completion of follow-up (estimated to be 4 years)]
Endometrial cancer-free survival [Through completion of follow-up (estimated to be 4 years)]
Change in weight [From baseline to 2 years]
Change in Cancer Worry Impact Events Scale (CWIES) [At enrollment, 12 months, and end of treatment (estimated to be 2 years)]
The CWIES is a 15-item self-report measure evaluating stress reactions and traumatic experiences, specifically inquiring about cancer worry-specific distress. Range of values for each individual item will be a Likert Scale from 0-5. 0=not at all and 5=often. The higher the score, the more cancer-worry specific distress the participant has.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of histologically confirmed complex atypical endometrial hyperplasia or grade 1 endometrial cancer.
Patients with a previous diagnosis of AEH or grade 1 endometrial cancer who are already being followed with conservative management with oral or LNG-IUD progestin therapy are eligible.
For patients with a previous diagnosis of AEH or grade 1 endometrial cancer who have been placed on progestin prior to study entry, the duration of IUD or oral progestin use prior to trial entry should be less than or equal to 6 months.
Premenopausal woman with a uterus.
ECOG performance status of 0-2.
At least 18 years of age and no more than 45 years of age.
Interested in uterine preservation/fertility-sparing treatment.
BMI ≥ 30 kg/m^2.
Prior or current receipt of progestin is allowed as above. Willingness to undergo placement of LNG-IUD at the time of study entry.
Prior or current receipt of metformin is allowed.
Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria:

Prior participation in a weight loss intervention trial within 3 months prior to date of registration.
Current, active treatment for any malignant neoplasm with chemotherapy or radiation.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
Pregnant and/or breastfeeding. Participants must have a negative serum pregnancy test within 7 days of date of registration.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Washington University School of Medicine	Saint Louis	Missouri	United States	63110
2	University of New Mexico	Albuquerque	New Mexico	United States	87106
3	University of Oklahoma	Oklahoma City	Oklahoma	United States	73104